Stockscreener 앱 받기
2.53
4.12%
0.10
시간 외 거래:
2.43
-0.10
-3.95%
Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Buy Rating from HC Wainwright - MarketBeat
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com
Syros Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Q3 2024 Syros Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday - MarketBeat
Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks - Investing.com India
Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks By Investing.com - Investing.com Australia
Piper Sandler reaffirms overweight rating and $5 PT on Syros Pharmaceuticals stock - Investing.com UK
Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to "Hold" - MarketBeat
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.com - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - cnhinews.com
Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks By Investing.com - Investing.com South Africa
Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks - Investing.com India
575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World
Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex
Symphony Environmental Technologies (LON:SYM) Shares Down 13.8% - Defense World
Spyre Therapeutics Inc.’s results are impressive - US Post News
Farallon Capital Management LLC Buys Shares of 666,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Itau Unibanco Holding S.A. Takes $435,000 Position in Ross Stores, Inc. (NASDAQ:ROST) - Defense World
Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Canada Pension Plan Investment Board Acquires 509,700 Shares of Symbotic Inc. (NASDAQ:SYM) - Defense World
Symbotic (NASDAQ:SYM) Shares Up 2.1% - Defense World
Arm Joins the PHLX Semiconductor Sector Index℠ (SOX℠) - sharewise
The Principles of Low-Carbon Tectonics: As Lygos, Pyran accelerate, we look at the why, the where, and the when - Biofuels Digest
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World
Quarterly Metrics: Quick and Current Ratios for Symbotic Inc (SYM) - The Dwinnex
Wall Street analysts’ outlook for Symbotic Inc (SYM) - SETE News
Understanding the Risks of Investing in Syros Pharmaceuticals Inc. (SYRS) - Knox Daily
Siyata Mobile Inc (SYTA) expanding its growth trajectory ahead - SETE News
What is the investor’s view on Syros Pharmaceuticals Inc. (SYRS)? - US Post News
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - Simply Wall St
Syros Pharmaceuticals Inc. [SYRS] Shares Fall Approximately -60.45% Over the Year - Knox Daily
Syros Pharmaceuticals Inc.’s Shares Reel: -70.93% Quarterly Revenue Decline Amid 41.97M Market Cap - The InvestChronicle
Syros pharmaceuticals CEO buys shares worth over $160k By Investing.com - Investing.com Australia
SYRS underperforms with a -2.18 decrease in share price - US Post News
Syros pharmaceuticals CEO buys shares worth over $160k - Investing.com
Syros Pharmaceuticals CFO buys shares worth over $161k - Investing.com
Insider Buying: President & CEO Conley Chee Acquires Shares of S - GuruFocus.com
Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) By GuruFocus - Investing.com Canada
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) By GuruFocus - Investing.com Canada
Syros Pharmaceuticals CFO buys shares worth over $161k By Investing.com - Investing.com Canada
Syros Pharmaceuticals stock hits 52-week low at $1.48 By Investing.com - Investing.com Australia
Syros Pharmaceuticals stock hits 52-week low at $1.48 - Investing.com
2.02%
0.47%
자본화:
|
볼륨(24시간):